HIV transmission risk persists during the first 6 months of antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 72, Issue 5, 2016, Pages 579-584

  Mujugira, Andrew ^a   Celum, Connie ^a   Coombs, Robert W ^a   Campbell, James D ^b   Ndase, Patrick ^a   Ronald, Allan ^c   Were, Edwin ^d   Bukusi, Elizabeth A ^e   Mugo, Nelly ^e   Kiarie, James ^f   Baeten, Jared M ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MANITOBA   (Canada)

^d MOI UNIVERSITY   (Kenya)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

antiretroviral therapy; HIV transmission; serodiscordant couples; viral suppression

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR DISOPROXIL; VIRUS RNA; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; COHORT ANALYSIS; CONDOM; CONFERENCE PAPER; FEMALE; HETEROSEXUALITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KENYA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRE-EXPOSURE PROPHYLAXIS; PREGNANCY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK REDUCTION; SEXUAL BEHAVIOR; SPERM; SURVIVAL ANALYSIS; TREATMENT DURATION; UGANDA; UNPROTECTED SEX; UTERINE ENDOCERVIX; VIRUS INHIBITION; VIRUS TRANSMISSION; DISEASE TRANSMISSION; DRUG EFFECTS; EPIDEMIOLOGY; GENETICS; HIGH RISK BEHAVIOR; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; PREVENTION AND CONTROL; RISK FACTOR; SEXUALITY; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TRANSMISSION; UTERINE CERVIX; VIROLOGY; VIRUS LOAD; VIRUS SHEDDING;

ANTI-HIV AGENTS; CERVIX UTERI; DISEASE TRANSMISSION, INFECTIOUS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KENYA; MALE; PROSPECTIVE STUDIES; RISK FACTORS; RISK-TAKING; RNA, VIRAL; SEMEN; SEXUAL BEHAVIOR; SEXUAL PARTNERS; TIME FACTORS; UGANDA; VIRAL LOAD; VIRUS SHEDDING;

EID: 84963646053     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001019     Document Type: Conference Paper

References (26)

1. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000; 342: 921-929
2. Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV RNA predicts risk of heterosexual HIV transmission. Sci Transl Med. 2011; 3: 77ra29
3. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV infection with early antiretroviral therapy. N Engl J Med. 2011; 365: 493-505
4. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIVinfected compartments during combination therapy. Nature. 1997; 387: 188-191
5. Hilldorfer BB, Cillo AR, Besson GJ, et al. New tools for quantifying HIV reservoirs: blood RNA single copy assays and beyond. Curr HIV/AIDS Rep. 2012; 9: 91-100
6. Andrade A, Rosenkranz SL, Cillo AR, et al. Three distinct phases of HIV RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248. J Infect Dis. 2013; 208: 884-891
7. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA. 2012; 308: 387-402
8. Mujugira A, Baeten JM, Donnell D, et al. Characteristics of HIV serodiscordant couples enrolled in a clinical trial of antiretroviral preexposure prophylaxis for HIV prevention. PLoS One. 2011; 6: e25828
9. Baeten JM, Donnell D, Mugo NR, et al. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV acquisition: an update of data from a randomised, double-blind, phase 3 trial. Lancet Infect Dis. 2014; 14: 1055-1064
10. Bourlet T, Levy R, Maertens A, et al. Detection and characterization of hepatitis C virus RNA in seminal blood and spermatozoon fractions of semen from patients attempting medically assisted conception. J Clin Microbiol. 2002; 40: 3252-3255
11. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367: 399-410
12. Cohen M, Chen Y, McCauley T, et al. Final results of the HPTN 052 randomized controlled trial: antiretroviral therapy prevents HIV transmission. Presented at: 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22, 2015; Vancouver, Canada
13. Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet. 2010; 375: 2092-2098
14. Apondi R, Bunnell R, Ekwaru JP, et al. Sexual behavior and HIV transmission risk of Ugandan adults taking antiretroviral therapy: 3 year follow-up. AIDS. 2011; 25: 1317-1327
15. Melo MG, Santos BR, De Cassia Lira R, et al. Sexual transmission of HIV among serodiscordant couples in Porto Alegre, southern Brazil. Sex Transm Dis. 2008; 35: 912-915
16. Reynolds SJ, Makumbi F, Nakigozi G, et al. HIV transmission among HIV discordant couples before and after the introduction of antiretroviral therapy. AIDS. 2011; 25: 473-477
17. Del Romero J, Castilla J, Hernando V, et al. Combined antiretroviral treatment and heterosexual transmission of HIV: cross sectional and prospective cohort study. BMJ. 2010; 340: c2205
18. Supervie V, Viard JP, Costagliola D, et al. Heterosexual risk of HIV transmission per sexual act under combined antiretroviral therapy: systematic review and bayesian modeling. Clin Infect Dis. 2014; 59: 115-122
19. Rodger A, Cambiano V, Bruun T, et al. HIV transmission risk through condomless sex if the HIV positive partner is on suppressive ART: PARTNER study. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI 2014); March 3-6, 2014; Boston, MA
20. Rodger AJ, Bruun T, Vernazza P, et al. Further research needed to support a policy of antiretroviral therapy as an HIV prevention initiative. Antivir Ther. 2013; 18: 285-287
21. Jean K, Gabillard D, Moh R, et al. Effect of early antiretroviral therapy on sexual behaviors and HIV transmission risk among adults with diverse heterosexual partnership statuses in Cote d?Ivoire. J Infect Dis. 2014; 209: 431-440
22. Heffron R, Were E, Celum C, et al. A prospective study of contraceptive use among African women in HIV serodiscordant partnerships. Sex Transm Dis. 2010; 37: 621-628
23. Kaida A, Matthews LT, Kanters S, et al. Incidence and predictors of pregnancy among a cohort of HIV-positive women initiating antiretroviral therapy in Mbarara, Uganda. PLoS One. 2013; 8: e63411
24. Mujugira A, Heffron R, Celum C, et al. Fertility intentions and interest in early antiretroviral therapy among East African HIV-infected individuals in serodiscordant partnerships. J Acquir Immune Defic Syndr. 2013; 63: e33-e35
25. Ngure K, Mugo N, Celum C, et al. A qualitative study of barriers to consistent condom use among HIV serodiscordant couples in Kenya. AIDS Care. 2012; 24: 509-516
26. Baeten JM, Heffron R, Kidoguchi L, et al. Near elimination of HIV transmission in a demonstration project of PrEP and ART. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI 2015); February 23-26, 2015; Seattle, Washington